Page 938 - Williams Hematology ( PDFDrive )

912 Part VI: The Erythrocyte Chapter 58: The Porphyrias 913

252. Eales L, Day RS, Blekkenhorst GH: The clinical and biochemical features of variegate 284. Calvert GM, Sweeney MH, Fingerhut MA, et al: Evaluation of porphyria cutanea
porphyria: An analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int tarda in U.S. workers exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Am J Ind Med
J Biochem 12(5–6):837, 1980. 25(4):559, 1994.
253. Grandchamp B, Phung N, Nordmann Y: Homozygous case of hereditary coproporphy- 285. Smith A: Porphyria caused by chlorinated AH receptor ligands and associated mecha-
ria. Lancet 2(8052–8053):1348, 1977. nisms of liver injury and cancer, in Porphyrin Handbook, Part II, edited by Kadish KM,
254. To-Figueras J, Badenas C, Enriquez MT, et al: Biochemical and genetic characteriza- Smith K, Guilard RR, p 169. Academic Press, San Diego, 2003.
tion of four cases of hereditary coproporphyria in Spain. Mol Genet Metab 85(2):160, 286. Brady JJ, Jackson HA, Roberts AG, et al: Co-inheritance of mutations in the uropor-
2005. phyrinogen decarboxylase and hemochromatosis genes accelerates the onset of por-
255. Nordmann Y, Grandchamp B, de Verneuil H, et al: Harderoporphyria: A variant phyria cutanea tarda. J Invest Dermatol 115(5):868, 2000.
hereditary coproporphyria. J Clin Invest 72(3):1139, 1983. 287. Barzilay D, Orion E, Brenner S: Porphyria cutanea tarda triggered by a combination of
256. Blake D, McManus J, Cronin V, et al: Fecal coproporphyrin isomers in hereditary three predisposing factors. Dermatology 203(2):195, 2001.
coproporphyria. Clin Chem 38:96, 1992. 288. Au WY, Tam SC, Ho KM, et al: Hypertrichosis due to porphyria cutanea tarda associ-
257. Hift RJ, Davidson BP, van der Hooft C, et al: Plasma fluorescence scanning and fecal ated with blastic transformation of myelofibrosis. Br J Dermatol 141(5):932, 1999.
porphyrin analysis for the diagnosis of variegate porphyria: Precise determination of 289. Lee SC, Yun SJ, Lee JB, et al: A case of porphyria cutanea tarda in association with
sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as idiopathic myelofibrosis and CREST syndrome. Br J Dermatol 144(1):182-5, 2001.
a reference standard. Clin Chem 50(5):915, 2004. 290. Anderson KE, Goeger DE, Carson RW, et al: Erythropoietin for the treatment of por-
258. Lamoril J, Puy H, Gouya L, et al: Neonatal hemolytic anemia due to inherited hardero- phyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 322:315,
porphyria: Clinical characteristics and molecular basis. Blood 91(4):1453, 1998. 1990.
259. Tio TH, Leijnse B, Jarrett A, et al: Acquired porphyria from a liver tumor. Clin Sci Mol 291. Armstrong DK, Sharpe PC, Chambers CR, et al: Hepatoerythropoietic porphyria: A
Med 16:517, 1959. missense mutation in the UROD gene is associated with mild disease and an unusual
260. Elder GH, Urquhart AJ, de Salamanca RE, et al: Immunoreactive uroporphyrinogen porphyrin excretion pattern. Br J Dermatol 151(4):920, 2004.
decarboxylase in the liver in porphyria cutanea tarda. Lancet 2:229, 1985. 292. Elder GH: The metabolism of porphyrins of the isocoproporphyrin series. Enzyme
261. Phillips JD, Jackson LK, Bunting M, et al: A mouse model of familial porphyria cutanea 17(1):61, 1974.
tarda. Proc Natl Acad Sci U S A 98(1):259, 2001. 292a. Poh-Fitzpatrick MB, Lamola AA: Direct spectrophotometry of diluted erythrocytes
261a. Sinclair PR, Gorman N, Shedlofsky SI, et al: Ascorbic acid deficiency in porphyria cutanea and plasma: A rapid diagnostic method in primary and secondary porphyrinemias. J
tarda. J Lab Clin Med 130:197–201, 1997. Lab Clin Med 87:362, 1976.
262. Gorman N, Zaharia A, Trask HS, et al: Effect of iron and ascorbate on uroporphy- 293. Poh-Fitzpatrick MB, Sosin AE, Bemis J: Porphyrin levels in plasma and erythrocytes of
ria in ascorbate-requiring mice as a model for porphyria cutanea tarda. Hepatology chronic hemodialysis patients. J Am Acad Dermatol 7:100, 1982.
45(1):187, 2007. 294. Topi GC, Amantea A, Griso D: Recovery from porphyria cutanea tarda with no spe-
263. Rocchi E, Casalgrandi G, Masini A, et al: Circulating pro- and antioxidant factors cific therapy other than avoidance of hepatic toxins. Br J Dermatol 111(1):75, 1984.
in iron and porphyrin metabolism disorders. Ital J Gastroenterol Hepatol 31(9):861, 295. Ippen H: Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol 14:253,
1999. 1977.
264. Sinclair PR, Gorman N, Walton HS, et al: CYP1A2 is essential in murine uroporphyria 296. Rocchi E, Cassanelli M, Ventura E: High weekly intravenous doses of desferrioxamine
caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 162(1):60, 2000. in porphyria cutanea tarda. Br J Dermatol 117:393, 1987.
265. Smith AG, Francis JE, Walters DG, et al: Protection against iron-induced uroporphyria 297. Ratnaike S, Blake D, Campbell D, et al: Plasma ferritin levels as a guide to the treatment
in C57BL/10ScSn mice by the peroxisome proliferator nafenopin. Biochem Pharmacol of porphyria cutanea tarda by venesection. Australas J Dermatol 29:3, 1988.
40(11):2564, 1990. 298. Ashton RE, Hawk JLM, Magnus IA: Low-dose oral chloroquine in the treatment of
266. Elder GH: Porphyria cutanea tarda and related disorders, in Porphyrin Handbook, Part porphyria cutanea tarda. Br J Dermatol 3:609, 1984.
II, edited by Kadish KM, Smith K, Guilard R, p 67. Academic Press, San Diego, 2003. 299. Bruce AJ, Ahmed I: Childhood-onset porphyria cutanea tarda: Successful therapy
267. Phillips JD, Parker TL, Schubert HL, et al: Functional consequences of naturally occur- with low-dose hydroxychloroquine (Plaquenil). J Am Acad Dermatol 38(5 Pt 2):810,
ring mutations in human uroporphyrinogen decarboxylase. Blood 98(12):3179, 2001. 1998.
268. Cassiman D, Vannoote J, Roelandts R, et al: Porphyria cutanea tarda and liver disease. 300. Freesemann A, Frank M, Sieg I, et al: Treatment of porphyria cutanea tarda by the
A retrospective analysis of 17 cases from a single centre and review of the literature. effect of chloroquine on the liver. Skin Pharmacol 8(3):156, 1995.
Acta Gastroenterol Belg 71(2):237, 2008. 301. Kordac V, Semradova M: Treatment of porphyria cutanea tarda with chloroquine. Br J
269. Gisbert JP, Garcia-Buey L, Alonso A, et al: Hepatocellular carcinoma risk in patients Dermatol 90(1):95, 1974.
with porphyria cutanea tarda. Eur J Gastroenterol Hepatol 16(7):689, 2004. 302. Taljaard JJF, Shanley BC, Stewart-Wynne EG, et al: Studies on low dose chloroquine
270. Rossmann-Ringdahl I, Olsson R: Porphyria cutanea tarda in a Swedish population: therapy and the action of chloroquine in symptomatic porphyria. Br J Dermatol
Risk factors and complications. Acta Derm Venereol 85(4):337, 2005. 87:261, 1972.
271. Dabski C, Beutner EH: Studies of laminin and type IV collagen in blisters of porphyria 303. Timonen K, Niemi KM, Mustajoki P: Skin morphology in porphyria cutanea tarda
cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol 25(1 Pt 1):28, does not improve despite clinical remission. Clin Exp Dermatol 16(5):355, 1991.
1991. 304. Thornsvard CT, Guider BA, Kimball DB: An unusual reaction to chloroquine-
272. Pigatto PD, Polenghi MM, Altomare GF, et al: Complement cleavage products in the primaquine. JAMA 235:1719, 1976.
phototoxic reaction of porphyria cutanea tarda. Br J Dermatol 114(5):567, 1986. 305. Sweeney GD, Jones KG: Porphyria cutanea tarda: Clinical and laboratory features. Can
273. Jalil S, Grady JJ, Lee C, Anderson KE: Associations among behavior-related suscepti- Med Assoc J 120:803, 1979.
bility factors in porphyria cutanea tarda. Clin Gastro Hepatol 8:297–302, 2010. 306. Malkinson FD, Levitt L: Hydroxychloroquine treatment of porphyria cutanea tarda.
274. Ajioka RS, Phillips JD, Weiss RB, et al: Down-regulation of hepcidin in porphyria cut- Arch Dermatol 116(10):1147, 1980.
anea tarda. Blood 112(12):4723, 2008. 307. Singal AK, Kormos-Hallberg C, Lee C, et al: Low-dose hydroxychloroquine is as effec-
275. Bulaj ZJ, Franklin MR, Phillips JD, et al: Transdermal estrogen replacement therapy tive as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gas-
in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin troenterol Hepatol 10(12):1402, 2012.
Med 136(6):482, 2000. 308. Stolzel U, Kostler E, Schuppan D, et al: Hemochromatosis (HFE) gene mutations
276. Wickliffe JK, Abdel-Rahman SZ, Lee C, et al: CYP1A2*1F and GSTM1 alleles are asso- and response to chloroquine in porphyria cutanea tarda. Arch Dermatol 139(3):309,
ciated with susceptibility to porphyria cutanea tarda. Molec Med 17:241-247, 2011. 2003.
277. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al: Porphyria cutanea tarda. Clini- 309. Egger NG, Goeger DE, Anderson KE: Effects of chloroquine in hematoporphy-
cal features and laboratory findings in 40 patients. Am J Med 67(2):277, 1979. rin-treated animals. Chem Biol Interact 102:69, 1996.
278. Sixel-Dietrich F, Doss M: Hereditary uroporphyrinogen-decarboxylase deficiency pre- 310. Cohen SN, Phifer KO, Yielding KL: Complex formation between chloroquine and fer-
disposing porphyria cutanea tarda (chronic hepatic porphyria) in females after oral rihaemic acid in vitro, and its effect on the antimalarial action of chloroquine. Nature
contraceptive medication. Arch Dermatol Res 278(1):13, 1985. 202:805, 1964.
279. Legault N, Sabik H, Cooper SF, et al: Effect of estradiol on the induction of porphyria 311. Scholnick PL, Epstein J, Marver HS: The molecular basis of the action of chloroquine
by hexachlorobenzene in the rat. Biochem Pharmacol 54(1):19, 1997. in porphyria cutanea tarda. J Invest Dermatol 61(4):226, 1973.
280. Fujita N, Sugimoto R, Motonishi S, et al: Patients with chronic hepatitis C achieving 311a. Solis C, Martinez-Bermejo A, Naidich TP, et al: Acute intermittent porphyria: Stud-
a sustained virological response to peginterferon and ribavirin therapy recover from ies of the severe homozygous dominant disease provides insights into the neurologic
impaired hepcidin secretion. J Hepatol 49(5):702, 2008. attacks in acute porphyrias. Arch Neurol 61:1764, 2004.
281. Wissel PS, Sordillo P, Anderson KE, et al: Porphyria cutanea tarda associated with the 312. Chlumska A, Chlumsky J, Malina L: Liver changes in porphyria cutanea tarda patients
acquired immune deficiency syndrome. Am J Hematol 25(1):107, 1987. treated with chloroquine. Br J Dermatol 102:261, 1980.
282. Roberts AG, Whatley SD, Nicklin S, et al: The frequency of hemochromatosis-asso- 313. Vizethum W, Dahlmann D, Bolsen K, et al: Influence of chloroquine (Resochin) on
ciated alleles is increased in British patients with sporadic porphyria cutanea tarda. hexachlorobenzene (HCB) induced porphyria of the rat. Arch Dermatol Res 264:125,
Hepatology 25(1):159, 1997. 1979.
283. Dereure O, Aguilar-Martinez P, Bessis D, et al: HFE mutations and transferrin receptor 314. Fernandez I, Castellano G, de Salamanca RE, et al: Porphyria cutanea tarda as a pre-
polymorphism analysis in porphyria cutanea tarda: A prospective study of 36 cases dictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gas-
from southern France. Br J Dermatol 144(3):533, 2001. troenterol 38(3):314, 2003.

Kaushansky_chapter 58_p0889-0914.indd 913 9/18/15 5:58 PM